{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:03:19Z","timestamp":1787061799470,"version":"build-2736575974"},"reference-count":38,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2015,5,20]],"date-time":"2015-05-20T00:00:00Z","timestamp":1432080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      IPX066 (extended\u2010release carbidopa\u2010levodopa [ER CD\u2010LD]) is an oral extended\u2010release capsule formulation of carbidopa and levodopa. The single\u2010dose pharmacokinetics of ER CD\u2010LD (as 2 capsules; total dose, 97.5\u2009mg\u2010390\u2009mg CD\u2010LD) versus immediate\u2010release (IR) CD\u2010LD (25\u2009mg\u2010100\u2009mg), sustained\u2010release (CR) CD\u2010LD (25\u2009mg\u2010100\u2009mg), and CD\u2010LD\u2010entacapone (25\u2009mg\u2010100\u2009mg\u2010200\u2009mg) was evaluated in healthy subjects. Following IR dosing, LD reached peak concentrations (C\n                      <jats:sub>max<\/jats:sub>\n                      ) at 1 hour; LD concentrations then decreased rapidly and were less than 10% of peak by 5 hours. With CR CD\u2010LD and CD\u2010LD\u2010entacapone, LD C\n                      <jats:sub>max<\/jats:sub>\n                      occurred at 1.5 hours, and concentrations were less than 10% of peak by 6.3 and 7.5 hours, respectively. The initial increase in LD concentration was similar between ER CD\u2010LD and IR CD\u2010LD and faster than for CR CD\u2010LD and CD\u2010LD\u2010entacapone. LD concentrations from ER CD\u00ad\u00ad\u2010LD were sustained for approximately 5 hours and did not decrease to 10% of peak until 10.1 hours. Dose\u2010normalized LD C\n                      <jats:sub>max<\/jats:sub>\n                      values for ER CD\u2010LD were significantly lower (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; .05) than for the other CD\u2010LD products. Bioavailability of LD from ER CD\u2010LD was 83.5%, 78.3%, and 58.8% relative to IR CD\u2010LD, CR CD\u2010LD, and CD\u2010LD\u2010entacapone, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jcph.514","type":"journal-article","created":{"date-parts":[[2015,4,8]],"date-time":"2015-04-08T17:26:16Z","timestamp":1428513976000},"page":"995-1003","source":"Crossref","is-referenced-by-count":77,"title":["Comparison of the pharmacokinetics of an oral extended\u2010release capsule formulation of carbidopa\u2010levodopa (IPX066) with immediate\u2010release carbidopa\u2010levodopa (Sinemet\n                    <sup>\u00ae<\/sup>\n                    ), sustained\u2010release carbidopa\u2010levodopa (Sinemet\n                    <sup>\u00ae<\/sup>\n                    CR), and carbidopa\u2010levodopa\u2010entacapone (Stalevo\n                    <sup>\u00ae<\/sup>\n                    )"],"prefix":"10.1002","volume":"55","author":[{"given":"Ann","family":"Hsu","sequence":"first","affiliation":[{"name":"Impax Specialty Pharma a division of Impax Laboratories, Inc. Hayward CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan\u2010Ming","family":"Yao","sequence":"additional","affiliation":[{"name":"Impax Specialty Pharma a division of Impax Laboratories, Inc. Hayward CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneel","family":"Gupta","sequence":"additional","affiliation":[{"name":"Impax Specialty Pharma a division of Impax Laboratories, Inc. Hayward CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishit B.","family":"Modi","sequence":"additional","affiliation":[{"name":"Impax Specialty Pharma a division of Impax Laboratories, Inc. Hayward CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,5,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.suppl_1.S19"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct0800326"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02697.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02371.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645020-00001"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20458"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199855001-00001"},{"issue":"2","key":"e_1_2_7_9_1","first-page":"7","article-title":"Rationale for continuous dopaminomimetic therapy of Parkinson's disease","volume":"39","author":"Chase TN","year":"1989","journal-title":"Neurology."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2003.013912"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.62.1_suppl_1.S9"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.9.1131"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.25.12.1144"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410200213"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130222"},{"issue":"2","key":"e_1_2_7_16_1","first-page":"25","article-title":"Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies","volume":"39","author":"Yeh KC","year":"1989","journal-title":"Neurology."},{"issue":"1","key":"e_1_2_7_17_1","first-page":"S29","article-title":"Clinical studies with and pharmacokinetic considerations of sustained\u2010release levodopa","volume":"42","author":"LeWitt PA.","year":"1992","journal-title":"Neurology."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000215875"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199502000-00006"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199304000-00007"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315512"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425240902870405"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22060"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.6.905"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.37.7.1242"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.2.210"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23861"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198610000-00003"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199410000-00005"},{"issue":"2","key":"e_1_2_7_30_1","first-page":"45","article-title":"Controlled\u2010release carbidopa\/ levodopa (Sinemet 50\/200 CR4): clinical and pharmacokinetic studies","volume":"39","author":"LeWitt PA","year":"1989","journal-title":"Neurology."},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)62690-1"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.36.6.739"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198904000-00002"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.1.70"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.63"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1985.tb00888.x"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2002.01654.x"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.2174\/157488407781668802"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050657"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.514","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.514","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.514","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.514","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T20:56:11Z","timestamp":1696366571000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,20]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1002\/jcph.514"],"URL":"https:\/\/doi.org\/10.1002\/jcph.514","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,20]]}}}